Tip Sheet 17: Review of Research by the Expedited Procedure

Similar documents
Expedited Review of Human Subject Research

Human Research Protection Program. Investigator Manual

Investigator Manual. Human Subjects Protection Program

Ethics Committees/IRBs Today: Challenges for Efficiency and Quality

Embryonic Stem Cell Research Oversight (ESCRO) Committee. Policies and Procedures

Trends in Oversight of Human Research Protections?

Rules of Human Experimentation

Outline of Discussion

Protection of Research Participants: The IRB Process and the Winds of Change

Recruitment of Subjects Best Practices

Human Subjects Protection: Training for Research Teams

INSTITUTIONAL REVIEW BOARD (IRB) AT CALIFORNIA PACIFIC MEDICAL CENTER GUIDELINES FOR RESEARCH INVOLVING HUMAN SUBJECTS. Assurance Number: FWA

GW Policy on Human Research Protection Program

TOP 10 INVESTIGATOR RESPONSIBILITIES WHEN CONDUCTING HUMAN SUBJECTS RESEARCH

S A I N T M A RY S E M I N A RY O C T O B E R 1 9,

What is an IRB (Institutional Review Board)?

Oklahoma City University s IRB Procedures and Guidelines

3. Human Biomedical Research. Defining Human Biomedical Research

Radiation - Florida Department of Health Institutional Review Board

Ethical Principles in Clinical Research

RESEARCH PERFORMANCE SITES AND COLLABORATIVE OFF-SITE RESEARCH

APPLICATION INSTRUCTIONS INSTITUTIONAL REVIEW BOARD. Revised January 2010 Page 1

Investigator Manual HRP-103

Streamlining IRB Procedures for Expanded Access

Certificate of Recognition (COR ) COR Program Guidelines. Infrastructure Health & Safety Association (IHSA) 05/17 1

Stony Brook University Human Stem Cell Research Policy (August 15, 2013 version)

WCG ACADEMY COURSE OVERVIEW

ClinicalTrials.gov Registration Guide

The Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Determination of IND/IDE Requirement

Institutional Review Board Compliance Elizabeth City State University

External IRB Review What Does it Mean for Your Institution

8 Most Significant Proposed Changes to the Common Rule. Susan L. Rose Office for the Protection of Research Subjects (OPRS)

The Nuremberg Doctor s Trial

CIOB CONFLICT OF INTEREST POLICY

Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework

Institutional Biosafety Committee. Policies and Procedures

HCCA: Compliance in Conducting Clinical Research: Conflict of Interest

UNIVERSITY of HOUSTON MANUAL OF ADMINISTRATIVE POLICIES AND PROCEDURES

A notice on the issuance of drug clinical trials, ethical review of the guiding principles

Investigator Conflict of Interest Disclosure Policy for Human Subjects Research

Institutional Biosafety Committee

The Revised Common Rule. Ann Johnson, PhD, MPH IRB Director University of Utah

Ethical Principles in Clinical Research. Disclaimer. Christine Grady Department of Bioethics NIH Clinical Center

Institutional Review Board for Use of Human and Animal Subjects in Research OIT

Expanded Access. to Investigational Drugs & Biologics. for Treatment Use

Contingent Workforce Solution (CWS) Programme

Review PROCESS, decision making PROCESS and communication BY

Model disciplinary procedure

Regulatory and ethical requirements in medical device studies. Finland

Please note that these flowcharts and checklists are from the IRB Researcher Manual.

How did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949

General Guidelines. In this sense, contribution of distinct individuals to the outcome of scientific analysis needs to be properly acknowledged.

CANCER CENTER SCIENTIFIC REVIEW COMMITTEE

Stanford University IRB Guidance On Data and Tissue Repositories

Clinical Trials Management for Molecular Diagnostics. April 2016

Please note that these flowcharts and checklists are from the IRB Researcher Manual.

\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management

EIGHT BASIC ELEMENTS OF INFORMED CONSENT

HCCA Compliance Institute

ARTICLE 29 DATA PROTECTION WORKING PARTY

Research: Ethics, Informed Consent, FDA, Off Label Use

2 : self-directing freedom and especially moral independence 3 : a self-governing state

FSC Forest Management Group System Procedures

Terms of Reference. Quality and Value Audits

Human Research Audit Program. Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance

Investigator Self-Assessment Checklist for Human Subjects Research

GDPR Compliance Checklist

RiskReporter. Using the best hiring practices. Managing volunteers at your organization Human resources checklist

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland

Standard Operating Procedures Guidelines for Good Clinical Practice

Participating on Evaluation Panels as a Peer Reviewer GUIDELINES. [Revised April 2015]

General Personal Data Protection Policy

Agenzia Italiana del Farmaco

Consent Language Does Affect Your Ability to Share

Developing an Environmental Compliance Plan

Applicability of US Regulations to Canadian Research

INTERNATIONAL STANDARD ON AUDITING 620 USING THE WORK OF AN AUDITOR S EXPERT CONTENTS

SETTING POLICIES and GUIDELINES for CONDUCTING INTERNAL INVESTIGATIONS

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria

Source Documents and Regulatory Binders October 6, 2016

ELECTRONIC DISTRIBUTION RULES

Hiring Procedures and Guidelines

Terminal Quality Management Process

Position Description

UPMC POLICY AND PROCEDURE MANUAL. Links to policies referenced within this policy can be found in Section V.

SUBJECT: INSTITUTIONAL REVIEW BOARD (IRB) - HUMANITARIAN USE DEVICES

PARTNERS HUMAN RESEARCH COMMITTEE. Human Tissues: Brief Primer on Research Use and Requirement for Partners IRB Review

CRISP Azure Migration Consulting Services. All responses due no later than Friday, July 21 st, at 5pm EST

Institutional Review Board (IRB)

Objectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents

THE BIOMEDICAL RESEARCH ETHICS COMMITTEE (BMREC)

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010

REGULATORY ISSUES: HOW TO APPLY FOR AN IND. Penny Jester and Maaike Everts

Institutional Review Board for the Protection of Human Subjects

Governance Policies for PCORnet, the National Patient-Centered Clinical Research Network

Application for Approval to Provide Legal Aid Services Guidelines

APPLICANT'S CHECKLIST

For Use By Certification Bodies Performing SAAS Accredited SA8000:2014 Certification Audits

MANUAL FOR HUMAN SUBJECTS RESEARCH

Transcription:

Tip Sheet 17: Review of Research by the Expedited Procedure Related Accreditation Elements: II.2.E. Policies and procedures should describe review using the expedited procedure, when an expedited procedure is used. Recommended Content: This policy and procedure may stand alone or be part of an umbrella policy and procedure on IRB or EC review. Application procedure: 1. Describe the materials that must be submitted to the IRB or EC, including information to judge eligibility for review by the expedited procedure. Reviewers: 1. Define when an IRB or EC member is considered experienced. 2. Describe the process by which the IRB or EC chair designates reviewers. Pre-Review Procedures: 1. Describe the entity (title of person or office), if any, that checks submissions for completeness and the actions taken when the submission is incomplete. 2. Describe the process used to decide whether the expedited procedure is used. 3. If reviewers using the expedited procedure relies on other supplemental reviews (e.g., consultants, staff, or subcommittee reviews), describe: a. When submissions receive such review. b. The entity that checks submissions to determine whether supplemental reviews are required and have been completed. c. The process by which reviewers learn the results of such reviews. 4. Describe the entity that checks for required special representation, such as a prisoner representative. 5. If more than one person can conduct reviews by the expedited procedure, describe: a. The entity that selects the person that conducts the review. b. The criteria used to make the selection. 6. If each research protocol or plan is reviewed by multiple persons, describe the procedure, including: a. The entity that determines that at least one reviewer has appropriate scientific and disciplinary expertise. b. The documents provided to all reviewers.

c. The documents provided only to specific reviewers. d. The timing of document distribution. e. The process used by the multiple reviewers to make a group decision. Review Procedures: 1. Describe the criteria for approval of research. 2. Describe responsibilities of reviewers, including: a. Conducts reviews with the same depth as that by a convened IRB or EC. b. Uses the same criteria for approval as for review by a convened IRB or EC. c. Declares conflicts of interest. d. Considers the need for additional expertise. e. For initial review: i. Documents the category of approval. ii. Determines that the research falls into one or more categories that allows review using an expedited procedure. iii. For DHHS- and FDA-regulated research, determines that the research meets the applicability criteria. (Include criteria to judge whether research involves no more than minimal risk to participants. Include criteria to judge whether identification of participants or their responses would reasonably place them at risk of criminal or civil liability or be damaging to their financial standing, employability, insurability, reputation, or be stigmatizing unless reasonable and appropriate protections will be implemented so that risks related to invasion of privacy and breach of confidentiality are no greater than minimal.) f. For continuing review: i. Determines that the research falls into one or more regulatory categories that allow continuing review using the expedited procedure. ii. Documents the category of approval. g. For review of modifications to previously approved research, determines that the proposed modification represents a minor change (include criteria to judge whether a modification represents a minor change). h. Completes checklists or other documentation, if any. i. Documents specific determinations required under the laws or regulations and protocol-specific findings that justify the determinations. j. Communicates with Researchers, if applicable. k. For continuing review, determines: i. That the current or proposed consent document is accurate and complete. ii. If any significant new findings that might relate to a participant s willingness to continue taking part in the research study need to be provided. iii. Whether verification from sources other than the Researcher is needed to ensure that no material changes have occurred since previous IRB or EC review.

Describe criteria to make such a determination. l. Other expectations, if applicable. 2. Describe the range of possible actions that can be taken, such as: m. Approval. n. Require modifications in order to secure approval. o. Other applicable actions allowed. 7. Describe actions that cannot be taken, including disapproval. 8. Describe when research protocols or plans are referred to the convened IRB or EC, such as: a. The reviewer cannot approve or approve with modifications. b. The reviewer can approve with modifications, but the Researcher does not agree with the requested modifications. c. Other situations, if applicable. 9. For initial and continuing review, describe: a. The process used by the reviewer determines the approval period including the criteria for which research protocol or plans require review more often than annually. b. The documentation of the approval period in records. Post-Review Procedures: 1. For initial and continuing review, describe: a. How the start date of the approval period is determined. b. How the last day of the approval period is determined. 2. Describe the process to inform IRB or EC members about research protocols or plans that have been approved using the expedited procedure. 3. Describe the process to report findings and actions from reviews using the expedited procedure to the Organization: a. Specify the organizational offices and officials that are notified. b. Describe the mechanism for notification. 4. If approved research requires further review by the Organization, describe: a. The required reviews. b. The process for communicating the results of those reviews to the IRB or EC. 5. Describe the process by which reports from the review are communicated to the Researcher: a. Date of review. b. What was reviewed. c. The process of review by the expedited procedure. d. The decisions of the reviewer. e. If the reviewer requires modifications in order to secure approval: i. A description of the required modifications. ii. The basis for requiring modifications.

6. When the reviewer requires modifications to the research protocol or plan in order to secure approval, describe the process for review of responsive materials. 7. Describe the process by which Researchers may respond in person or in writing to IRB or EC decisions. Additional Issues for Continuing Review: 1. Describe the consequences of the Researcher not providing continuing review information to the IRB or EC, or of the IRB or EC not reviewing and approving a research protocol or plan by the expiration date, such as: a. State that all research activities must stop, unless the IRB or EC finds an over-riding safety concern or ethical issue such that the best interests of individual participants are served by continuing. b. Describe the process the IRB or EC uses to determine whether there are currently enrolled participants with safety concerns or ethical issues that may arise if research activities are stopped. c. Describe the process to determine whether the best interests of individual participants are served by continued involvement in the research. d. Describe any other consequence, as applicable. Additional Issues for Review of Modifications to Previously Approved Research: 1. Indicate the required time frame for submission to the IRB or EC of: a. Changes initiated without IRB or EC review and approval to eliminate apparent immediate hazards to the participant. b. Proposed changes in a research activity. c. The completion of a research study. d. Other changes. 2. Describe the process to review modifications initiated prior to IRB or EC approval to eliminate apparent immediate hazards to determine whether changes are consistent with ensuring participants continued welfare.

Other Suggestions 1. If a checklist is used for initial review of research, include: a. Applicability criteria for eligibility for review by the expedited procedure. b. Categories of research eligible for review by the expedited procedure. c. Criteria for approval. 2. If a checklist is used for continuing review of research, include: a. Categories of research eligible for review by the expedited procedure. b. Criteria for approval. 3. If a checklist is used for initial review of research, include: a. The requirement that the modification be a minor change. b. Criteria for approval. 4. Include in supporting forms for Researchers: a. Submission requirements. b. Eligibility criteria for review of research by the expedited procedure. c. The required time frame for submission of study completion.